News | August 17, 2025
Alkem reports posts Q1 FY26 net profit 22% higher at 664.3 Cr
Alkem’s domestic business grew 9.7 per cent versus the Indian pharmaceutical market growth of 8.5 per cent
Alkem’s domestic business grew 9.7 per cent versus the Indian pharmaceutical market growth of 8.5 per cent
The company reported revenue from operations at Rs. 6,573.7 crore, up 6 per cent YoY
GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology
Revenue increased 11.4 per cent to Rs. 8,545 crore
Spikevax is now approved for all individuals aged 6 months through 64 years at increased risk for COVID-19 disease
Acquisition aligns with Merck’s science-led business development strategy and expands pipeline and portfolio of treatments for cardio-pulmonary diseases
A triple-action Formula for comprehensive respiratory relief
The approval in China is supported by a robust local clinical development program confirming the drug’s safety, tolerability, and efficacy profile
SUP will obtain regulatory approvals for selling Tiotropium DPI in China
Enflosina is a long-acting monoclonal antibody that provides direct protection for up to 5 months
Subscribe To Our Newsletter & Stay Updated
